He helped Gilead score billions from HIV, hepatitis C drugs — now he's building a cancer fighter
Norbert Bischofberger rides again.
The 62-year-old former chief scientific officer at Gilead Sciences Inc. (NASDAQ: GILD), who stepped down last month after overseeing the development of groundbreaking and sometimes-controversial HIV and hepatitis C drugs, will become president and CEO of Cambridge, Mass., cancer-fighting startup K ronos Bio Inc.
And Bischofberger, an investor in Kronos' $18 million seed round disclosed Wednesday, isn't alone: Also investing in the company is Gilead's executive…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Cancer | Cancer & Oncology | Health Management | Hepatitis | Hepatitis C | Pharmaceuticals